A recent series of letters were published in JBMR-A about platelet concentrates for surgical use, where both terminology and content of these materials were hotly debated. The deﬁnition and classiﬁcation of the platelet concentrate products are indeed very important issues, as many misunderstandings are widely spread in the large literature on this topic.
These techniques were initially gathered under the name ‘‘platelet-rich plasma (PRP),’’ in reference to the generic term used in transfusion hematology, but this name is too general for the qualiﬁcation of the many products developed now.
In the ﬁrst letter, Everts et al insisted on the presence of leukocytes in most platelet preparations for surgical use.
These authors explained a very important truth that many PRPs were in fact leukocyte- and platelet-rich plasmas (LPRPs), and that the presence of leukocytes in these surgical adjuvants may be highly beneﬁcial.
They thus, introduced the term of ‘‘platelet-leukocyte–rich plasma (P-LRP).’’ Moreover, they pointed out that the two activation forms of the product (liquid platelet suspension or geliﬁed ﬁbrin-platelet clot) have different characteristics, and that the concentrates activated with a ﬁbrinogen-cleaving agent (thrombin, batroxobin) should be named in fact as ‘‘platelet-leukocyte gels (PLG).’’ In this letter, these authors resumed the clariﬁcation process of the platelet concentrate deﬁnitions started in 2006. However, their proposals for terminology were not complete and have been improved and systematized in the recent publication of a wide classiﬁcation system for these products.
The ﬁrst concern is that all PRPs do not contain leukocytes. Many PRPs obtained from cell separator units or from the Anitua’s preparation rich in growth factors (PRGF) subfamilies do not contain leukocytes and were classiﬁed as pure PRP (P-PRP).
On the contrary, PRPs containing leukocytes were classiﬁed as L-PRP: this acronym seems obviously more logical and reader-friendly than P-LRP, but we agree that a consensus should be found to solve this issue once for good.
The second issue is related to the gel form terminology.
‘‘Platelet gel’’ and ‘‘PLG’’ are too general terms.
Indeed, products with a high-density ﬁbrin network also exist and were classiﬁed as ‘‘platelet-rich ﬁbrin (PRF),’’ some with leukocytes [leukocyte- and platelet-rich ﬁbrin (L-PRF)] and some without leukocytes [pure platelet-rich ﬁbrin (P-PRF)].
All these PRFs are only available in the form of a very dense ﬁbrin gel,6 while PRP gels are never so strong and dense.
We thus believe that the activated form of P-PRP or L-PRP should simply be named ‘‘P-PRP gel’’ and ‘‘L-PRP gel’’ to differentiate them from the products of the PRF families. In the second letter, Anitua et al agreed that the recent development of many different techniques with various platelet and leukocyte contents led to a confusing jungle of terms and products.
This notion of ‘‘jungle of platelet concentrates’’ was already pointed out some years ago,8 when the main confusion between PRPs and the ﬁrst PRF appeared. Anitua et al. were right in their call for the deﬁnition of a relevant terminology but their approach was unfortunately partisan.
First, Anitua et al. claimed that leukocytes should be avoided in platelet concentrates for surgical use, to avoid the proinﬂammatory effects of the proteases and acid hydrolases contained in white blood cells, particularly when injected in tendons.
However, these authors did not justify their statement with scientiﬁc evidence; to sustain their claim, Anitua et al. cited Ref. describing very positive anabolic effects on tendon cells obtained with a PRP, …but the PRP described in this study was in fact a leukocyte-rich PRP.
This question of the leukocyte content within platelet concentrates for surgical use is in fact an old debate.
There is however actually no proof that the leukocytes within these surgical preparations might have undesirable side effects. On the contrary, several studies showed that L-PRPs have antimicrobial effects, but no undesirable inﬂammatory reactions have been observed with L-PRPs 1280 V C 2010 WILEY PERIODICALS, INC. up to now, even in immune sensitive applications.
From our standpoint, the inﬂuence of leukocytes injected with surgical platelet concentrates is actually a relevant way of research, and no author can claim that their inﬂuence is negative.
All statements on this matter should be carefully and scientiﬁcally discussed and proven.
The second controversial statement is related to the term ‘‘PRGF’’ used to deﬁne Dr. Anitua’s products and is a good illustration of the confusion induced by the superposition of trademarks and terminology. Described in 1999 by Anitua, the PRGF (plasma19 or preparation20 rich in growth factors) protocol is a manual procedure for the production of a P-PRP with a moderate platelet concentration increase.
The PRGF trademarks and associated patents are the proprietary of Dr. Anitua and Biotechnology Institute (BTI, a dental implant company, the ‘‘BTI’’ trademark being the proprietary of Dr. Anitua also), as it was published in the international trademark and patent database of the World Intellectual Property Organization.
Whatever the conﬂict of interest, it is obvious that the PRGF technology, with the different possible variations described by Anitua et al., generates products with a light ﬁbrin network and no leukocyte, and thus clearly belongs to the PPRP family.
We agree with Dr. Anitua that giving a speciﬁc name to a speciﬁc product such as PRGF is of great help to identify techniques and the associated literature.
However, we also believe that this commercial strategic approach should remain reasonable and evidence based. It is not possible to consider PRGF as something fundamentally different from the other P-PRP without true scientiﬁc justiﬁcation other than the claims of the company.
When a trademark is used without caution as a scientiﬁc denomination, it induces confusion and raises suspicion of commercialism. The risk is then to discredit the whole database produced by Dr. Anitua about his P-PRP, while these data are very interesting for a better understanding of the biological differences between the four main classiﬁed families of products.
As a conclusion, it is now very important to ﬁnd a terminology consensus on platelet concentrates technologies, to avoid confusions in this wide and complex ﬁeld of research, particularly concerning the role of leukocytes and the ﬁbrin architecture.
In many articles, the lack of characterization of the tested products (such as the leukocyte content) made the literature in this ﬁeld very difﬁcult to sort and interpret. Without a consensus, this ﬁeld will remain opaque and this situation will considerably restrain its development.
Dohan Ehrenfest Department of Biomaterials, Institute for Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Sweden The LoB5 Foundation for Research, Paris, France
Department and Clinic of Orthopaedics, Medical University of Silesia, Sosnowiec, Poland
Marco Del Corso
Private Practice, Turin, Italy Department of Odontostomatological and Maxillofacial Sciences, University Federico II of Naples, Italy
Department of Dental Sciences and Surgery, University of Bari, Italy
Department of Odontostomatological and Maxillofacial Sciences, University Federico II of Naples, Italy
1. Everts PA, van Zundert A, Schonberger JP, Devilee RJ, Knape JT. What do we use: Platelet-rich plasma or platelet-leukocyte gel? J Biomed Mater Res A 2008;85:1135–1136.
2. Anitua E, Sanchez M, Orive G, Andia I. Shedding light in the controversial terminology for platelet rich products. J Biomed Mater Res A 2009;90:1262–1263.
3. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classiﬁcation of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich ﬁbrin (L-PRF). Trends Biotechnol 2009; 27:158–167.
4. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638–646.
5. Bielecki T, Gazdzik TS, Szczepanski T. Re: ‘‘The effects of local platelet rich plasma delivery on diabetic fracture healing’’. What do we use: Platelet-rich plasma or platelet-rich gel? Bone 2006;39: 1388.
6. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun’s platelet-rich ﬁbrin clot and membrane. J Periodontol 2010; 81:546–555.
7. Fernandez-Barbero JE, Galindo-Moreno P, Avila-Ortiz G, Caba O, Sanchez-Fernandez E, Wang HL. Flow cytometric and morphological characterization of platelet-rich plasma gel. Clin Oral Implants Res 2006;17:687–693.
8. Dohan DM, Choukroun J. PRP, cPRP, PRF, PRG, PRGF, FC. How to ﬁnd your way in the jungle of platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103: 305–306.
9. Schnabel LV, Mohammed HO, Miller BJ, McDermott WG, Jacobson MS, Santangelo KS, Fortier LA. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in ﬂexor digitorum superﬁcialis tendons. J Orthop Res 2007;25: 230–240.
10. Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 2008;26:404–410.
11. Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, Cieslik T. Why the platelet-rich gel has antimicrobial activity? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:303–305.
12. Bielecki T, Gazdzik TS, Szczepanski T. Beneﬁt of percutaneous injection of autologous platelet-leukocyte-rich gel in patients with delayed union and nonunion. Eur Surg Res 2008;40: 289–296.
13. Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szczepanski T. Autologous platelets and leukocytes can improve ealing of infected high-energy soft tissue injury. Transfus Apher Sci 2009;41:9–12.
14. Everts PA, Devilee RJ, Brown Mahoney C, van Erp A, Oosterbos CJ, Stellenboom M, Knape JT, van Zundert A. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome. A prospective randomized double-blind study. Eur Surg Res 2008;40: 203–210.
15. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006;34:1774–1778.
16. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich ﬁbrin (PRF): A gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009; 27:63–69.
17. Dohan Ehrenfest DM, Diss A, Odin G, Doglioli P, Hippolyte MP, Charrier JB. In vitro effects of Choukroun’s PRF (platelet-rich ﬁbrin) on human gingival ﬁbroblasts, dermal prekeratinocytes, preadipo
cytes, and maxillofacial osteoblasts in primary cultures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:341–352.
18. Dohan Ehrenfest DM, Doglioli P, de Peppo GM, Del Corso M, Charrier JB. Choukroun’s platelet-rich ﬁbrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 2010; 55:185–194.
19. Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999;14:529–535.
20. Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical ﬁelds. Biomaterials 2007;28:4551–4560.
21. Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the platelet concentrate collection system with the plasmarich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants 2005;20: 118–123.